A small clump of human neural tissue sits in a dish, firing in patterns that resemble the EEG signatures of a premature infant. It is not a brain. It is not a person. But it is not not something, either — and the language we usually use for laboratory samples is starting to sound inadequate. This is the problem of brain organoids, and it is the problem right now.
A brain organoid is a three-dimensional cluster of neural cells grown from stem cells — typically induced pluripotent stem cells derived from adult donors. In the simplest form, they are tissue models used to study neurological disease, drug responses, or early brain development. The field dates back to the early 2010s, but what has accelerated since Films from the Future was published has not been the underlying technique so much as the questions the technique is now forcing into the open.
Three developments matter most. The first is assembloids — organoids from different brain regions fused together. Researchers at Stanford and elsewhere have built cortical-striatal, cortical-thalamic, and midline assembloids that begin to reconstruct the long-range wiring of real brains. Some current consciousness theories hold that integrated, inter-regional connectivity is a precondition for anything resembling experience. Assembloids do not clear that bar. But they move the bar closer, and the field has no clear method for deciding when it has been crossed.
The second is transplantation. In a 2022 paper in Nature, Sergiu Paşca’s Stanford group showed that human cortical organoids transplanted into the somatosensory cortex of newborn rats matured, integrated into the rats’ sensory circuits, and participated in motivation-related behavior. The human neurons grew six times larger than their in-dish counterparts and developed branching patterns that had been impossible to reproduce ex vivo. The study was scientifically elegant. It was also ethically strange: human-derived neural tissue, now embedded in another animal’s brain, responding to that animal’s experiences. Whose tissue is this? Whose experience?
The third is organoid intelligence. In 2023, a group led by Lena Smirnova at Johns Hopkins introduced the term “organoid intelligence” (OI) as a research programme distinct from AI and from brain-computer interfaces — one that treats cultured human neurons as substrates for biological computation. That programme is covered in Biological Computing, Wetware, and Bio-Silicon Hybrids. The two fields are not the same. They share a problem.
The governance is thin. The International Society for Stem Cell Research (ISSCR) 2021 guidelines treat brain organoids as ordinary tissue research — exempt from specialised ethical oversight — and a revision is under discussion. Beyond that framework, what exists is a scattered set of institutional review boards, national bioethics advisories, and self-regulation by the field itself. There is no international consensus on when an organoid acquires moral status. There is no agreement on what “moral status” even means in this context, because moral philosophy and neuroscience are asking different questions with different vocabularies, and the fusion of the two is nascent.
This is the book’s Permissionless Innovation pattern applied to a very particular substrate. Much of the foundational work happens in academic labs under the loose oversight of institutional review, and much of the commercialising work happens in companies where the review is still thinner. Capability is outpacing governance — not because anyone is acting badly, but because the frameworks that exist were not built for this.
The Too Valuable to Fail pattern is already visible. Organoid research is now load-bearing for parts of Alzheimer’s research, autism research, drug screening, and developmental neuroscience. A regulatory regime that dramatically restricted this work would have real human costs measured in delayed treatments. The question of whether such a regime is needed cannot be separated from the question of what we are willing to give up, and for what.
The most direct connection is to Never Let Me Go. The book’s central move in that chapter is to reject the framing it is handed. Society in the film has convinced itself that the clones are not fully human, and the book identifies this as the wrong question — not because clones obviously are or are not human, but because the question functions as avoidance. It lets the technology continue without reckoning with what is owed. As the book argues, the real question is not what are they? but what do we owe them?
That framework maps onto organoids almost too neatly. The dominant public-facing debate asks, “Are organoids conscious yet?” — and that debate is unresolvable with the tools we have, because there is no agreed definition of consciousness and no agreed threshold. A recent philosophical intervention puts it sharply: research on brain organoids should prioritise questions of agency, not consciousness. Which is another way of saying the book’s wrong-question move. The productive question is not whether a given cluster of neurons crosses some metaphysical line. It is what our relationship to that tissue ought to be, given what it is and what we are asking of it.
That reframing is the contribution the book offers. It does not resolve the science. It relocates the ethical conversation.
Applying the book’s other frameworks honestly:
Films from outside the book’s twelve sharpen the question. Possessor (2020, Brandon Cronenberg) asks where consciousness resides when a substrate can be occupied. Splice (2009) handles the moral-status-of-laboratory-creation question with less restraint and more honesty than most hand-wringing commentary. The Island (2005) is the obvious pair to Never Let Me Go, and shares its central evasion. All three are handled on Claude’s film recommendations; none of them resolve the problem, but they help frame it.